

IN THE CLAIMS

Please amend the Claims as follows:

1. (original) A complement inhibitor molecule that inhibits the classical complement pathway and the alternative complement pathway.
2. (original) A complement inhibitor molecule according to claim 1 which inhibits cleavage of C5 by classical and alternative C5 convertases.
3. (original) A complement inhibitor molecule that inhibits cleavage of C5 by a C5 convertase.
4. (original) A complement inhibitor molecule of claim 3, wherein the C5 convertase is a C5 convertase of the classical pathway.
5. (original) A complement inhibitor of claim 3, wherein the C5 convertase is a C5 convertase of the alternative complement pathway.
6. (currently amended) A complement inhibitor according to ~~any one of claim[[s]] 2 to 5~~ which inhibits cleavage of C5 by binding to C5.
7. (original) A complement inhibitor molecule according to claim 6 complexed with C5.
8. (currently amended) A complement inhibitor molecule according to ~~any one of claim[[s]] 1 to 7~~, which is derived from a haematophagous arthropod.
9. (original) A complement inhibitor molecule according to claim 8 wherein said haematophagous arthropod is a tick.
10. (original) A complement inhibitor molecule according to claim 9, wherein said tick is *Ornithodoros moubata*.
11. (original) A complement inhibitor molecule according to claim 10, comprising amino acids 19 to 168 of the amino acid sequence in Figure 4 or a functional equivalent thereof.

12. (original) A complement inhibitor molecule according to claim 10, comprising amino acids 1 to 168 of the amino acid sequence in Figure 4 or a functional equivalent thereof.
13. (original) A complement inhibitor molecule that inhibits the classical complement pathway and the alternative complement pathway, wherein said complement inhibitor is:
 - a) a protein comprising amino acids 19 to 168 or amino acids 1 to 168 of the amino acid sequence in Figure 4;
 - b) a homologue of a protein as defined in a) having at least 60% identity thereto; or
 - c) an active fragment of a protein as defined in a) above or of a homologue as defined in b) above.
14. (original) A complement inhibitor molecule that inhibits cleavage of C5 by a C5 convertase, wherein said complement inhibitor is:
 - a) a protein comprising amino acids 19 to 168 or amino acids 1 to 168 of the amino acid sequence in Figure 4;
 - b) a homologue of a protein as defined in a) having at least 60% identity thereto; or
 - c) an active fragment of a protein as defined in a) above or of a homologue as defined in b) above.
15. (original) A complement inhibitor molecule according to claim 14 which inhibits cleavage of C5 by direct binding to C5.
16. (original) A complement inhibitor molecule according to claim 15 complexed with C5.
17. (currently amended) An antibody which binds to a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 16~~.
18. (currently amended) A fusion protein comprising a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 17~~ that is genetically or chemically fused to one or more peptides or polypeptides.

19. (original) A fusion protein according to claim 18 wherein said complement inhibitor molecule or functional equivalent thereof is genetically or chemically fused to a marker domain.
20. (original) A fusion protein according to claim 19 wherein said marker domain is a radiochemical tag.
21. (currently amended) A nucleic acid molecule comprising a nucleotide sequence encoding a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 16~~ or a fusion protein ~~according to any one of claims 18 to 20 thereof~~, said fusion protein comprising said complement inhibitor molecule or functional equivalent thereof, that is genetically or chemically fused to one or more peptides or polypeptides.
22. (original) A nucleic acid molecule according to claim 21 comprising nucleotides 53 to 507 of the nucleotide sequence in Figure 4 or a functional equivalent thereof.
23. (original) A nucleic acid molecule according to claim 21 comprising nucleotides 1 to 507 of the nucleotide sequence in Figure 4 or a functional equivalent thereof.
24. (currently amended) An antisense nucleic acid molecule which hybridises under high stringency hybridisation conditions to a nucleic acid molecule according to ~~any one of claim[[s]] 21 to 23.~~
25. (currently amended) A vector comprising a nucleic acid molecule according to ~~any one of claim[[s]] 21 to claim 24~~ or an antisense nucleic acid molecule which hybridizes under high stringency conditions to said nucleic acid molecule.
26. (currently amended) A host cell comprising a nucleic acid molecule according to ~~any one of claim[[s]] 21 to 23~~, an antisense nucleic acid molecule which hybridizes under high stringency hybridization conditions to said nucleic acid molecule, ~~according to claim 24~~ or a vector ~~according to claim 25~~ comprising said nucleic acid molecule.
27. (currently amended) A method for preparing a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 16~~ or a fusion protein ~~according to claims 18 to 20 thereof~~, comprising culturing a host cell ~~according to claim 26~~ under conditions whereby said protein is expressed and recovering said protein thus produced, said host cell

comprising a nucleic acid molecule, an antisense nucleic acid molecule, or a vector, and said nucleic acid molecule comprising a nucleotide sequence encoding said complement inhibitor molecule or equivalent thereof.

28. (currently amended) A method of identifying a ligand of a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 16~~ comprising the step of:

(a) contacting the complement inhibitor molecule or functional equivalent thereof with a candidate ligand; and

(b) detecting the formation of a ligand-complement inhibitor molecule complex.

29. (currently amended) A composition comprising a complement inhibitor molecule according to ~~any one of claim[[s]] 1 to 16~~, a fusion protein thereof, ~~according to any one of claims 18 to 20~~, or a nucleic acid molecule comprising a nucleotide sequence encoding said complement inhibitor molecule or equivalent thereof, ~~according to any one claims 21 to 23~~ in conjunction with a pharmaceutically acceptable carrier.

30. (original) A composition according to claim 29 further comprising an adjuvant.

31. canceled

32. (currently amended) A method of treating an animal suffering from a complement-mediated disease or disorder or preventing an animal developing a complement-mediated disease or disorder comprising administering to said animal a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of claim[[s]] 1 to 16~~, a fusion protein thereof ~~according to any one of claims 18 to 20~~, a nucleic acid molecule comprising a nucleotide sequence encoding said complement inhibitor molecule or equivalent thereof, in conjunction with a pharmaceutically acceptable carrier ~~according to any one of claims 21 to 23~~, or a composition comprising any of the foregoing, ~~according to claim 29 or 30~~ in a therapeutically or prophylactically effective amount.

33. canceled

34. (currently amended) A method according to claim 32 ~~or use according to claim 33~~ wherein said disease or disorder is Alzheimer's disease, rheumatoid arthritis, glomerulonephritis, reperfusion injury, transplant rejection, sepsis, immune complex disorder or delayed-type hypersensitivity.
35. (currently amended) A method of vaccinating an animal against a disease or disorder transmitted by a haematophagous arthropod comprising administering to said animal a complement inhibitor molecule or a functional equivalent thereof according to ~~any one of~~ claim[[s]] 1 ~~to 16~~, a fusion protein thereof, ~~according to any one of claims 18 to 20~~, a nucleic acid molecule comprising a nucleotide sequence encoding said complement inhibitor molecule or equivalent thereof, in conjunction with a pharmaceutically acceptable carrier ~~according to any one of claims 21 to 23~~, or a composition of any of the foregoing ~~according to claim 29 or claim 30~~.
36. canceled
37. (currently amended) A method according to claim 35 ~~or use according to claim 36~~, wherein the haematophagous arthropod is *O. moubata*.
38. (currently amended) A method ~~or a use~~ according to claim 37 wherein the disease or disorder is relapsing fever, African swine fever or West Nile fever.
39. canceled
40. (currently amended) A method for inhibiting the classical and alternative complement pathways in a cell, tissue or non-human organism comprising administering to said cell, tissue or organism, a complement inhibitor according to ~~any one of~~ claim[[s]] 1 ~~to 16~~, a fusion protein thereof ~~according to claim 18-20~~, or a nucleic acid molecule comprising a nucleotide sequence encoding said complement inhibitor molecule or equivalent thereof, in conjunction with a pharmaceutically acceptable carrier ~~according to any one claims 21-23~~.